Back HCV Treatment

HCV Treatment

EASL 2011: BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon

Most prior non-responders with HCV genotype 1 achieved sustained response with a quadruple combination containing 2 experimental agents plus pegylated interferon/ribavirin, and nearly 40% did so using only the 2 oral drugs -- BMS-790052 and BMS-650032 -- researchers reported at EASL 2011. 

Read more:

EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine

76% of treatment-naive genotype 1 or 4 hepatitis C patients achieved 12-week sustained response to mericitabine (formerly RG7128) plus pegylated interferon/ribavirin, according to a report at EASL 2011. alt

Read more:

EASL 2011: Telaprevir Improves HCV Cure Rates Regardless of IL28B Status

The Vertex experimental protease inhibitor telaprevir, taken with pegylated interferon plus ribavirin, increased sustained response in people with all IL28B gene patterns, researchers reported at EASL 2011.

Read more:

EASL 2011: Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug

Almost all treatment-naive hepatitis C patients treated with Pharmasset's candidate PSI-7977 plus pegylated interferon/ribavirin experienced 12-week sustained response, and more than 90% treated with a PSI-7977 + PSI-938 all-oral combo had undetectable HCV at 14 days, researchers reported at EASL. alt

Read more:

Boceprevir Improves Response to Interferon-Based HCV Therapy

The HCV protease inhibitor boceprevir improved sustained response rates when combined with pegylated interferon plus ribavirin in both previously untreated patients and prior non-responders, according to findings from 2 studies published in the March 31 New England Journal of Medicine. alt

Read more: